Skip to main content

Table 2 Summary of patient demography and medication, with log-transformed power values of the LF, HF, and TP bands

From: The association of genetic polymorphisms in CYP1A2, UGT1A4, and ABCB1 with autonomic nervous system dysfunction in schizophrenia patients treated with olanzapine

 

All subjects (n = 91)

Age (years)

50.30 ± 15.25

Sex (male/female)

39/52

Inpatient/outpatient

21/70

Duration of illness (years)

19.28 ± 13.35

Smoking (smoker/non-smoker)

6/85

BMI (kg/m2)

24.01 ± 4.66

CPZeqa (mg/day)

491.21 ± 247.05

BPDeqb (mg/day)

0.78 ± 1.79

DZPeqc (mg/day)

7.62 ± 13.41

PANSS total score

72.16 ± 16.00

lnLF (ms2)

4.32 ± 1.12

lnHF (ms2)

3.81 ± 1.15

lnTotal Power (ms2)

4.93 ± 0.99

  1. Data are presented as the mean ± standard deviation
  2. BMI Body mass index, PANSS Positive and Negative Syndrome Scale, ln natural log-transformed, HF High frequency, LF Low frequency, TP Total power
  3. a The daily dosages of antipsychotic drugs were converted to approximate chlorpromazine equivalents
  4. b The daily dosages of anticholinergic antiparkinsonian drugs were converted to approximate biperiden equivalents
  5. c The daily dosages of benzodiazepine were converted to approximate diazepam equivalents